Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFLEXION double-blind extension in high-risk first demyelinating event and multiple sclerosis
2008-004954-34Phase 3Completed
- Sponsor
- Merck Serono
- Start
- Nov 2008
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, double-blind trial of interferon beta-1a in multiple sclerosis (MS) and clinically isolated syndrome (CIS) (2 arms), sponsored by Merck Serono. Primary endpoint: Time to conversion to clinically definite multiple sclerosis through Month 36. Started Nov 2008; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on 2008-004954-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004954-34.